Igenica
Biopharmaceutical company developing antibody-based therapeutics for the treatment of cancer.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD7—10m (Dealroom.co estimates Jun 2015.)
Burlingame California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$3.1m | Series A | ||
$24.0m | Series B | ||
$33.0m | Series C | ||
| N/A | $14.0m | Series C | |
$216k | Grant | ||
| N/A | $5.1m | Early VC | |
| N/A | $1.2m | Early VC | |
| Total Funding | CAD110m | ||
Related Content
Recent News about Igenica
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.